Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 945 drug-target rows in SSL view, for TSG = BARD1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib BARD1 KIT 7
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BARD1 KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BARD1 RET 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) BARD1 KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) BARD1 RET 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine BARD1 TYMS 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BARD1 KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BARD1 RET 3
capecitabine, cisplatin BARD1 TYMS 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan BARD1 TOP1MT 3
gemcitabine BARD1 TYMS 3
lurbinectedin, irinotecan BARD1 TOP1MT 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone BARD1 RXRB 3
pembrolizumab, belzutifan, lenvatinib BARD1 KIT 3
pembrolizumab, belzutifan, lenvatinib BARD1 RET 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab BARD1 TYMS 3
avapritinib BARD1 KIT 7
capecitabine BARD1 TYMS 7
pazopanib BARD1 KIT 7
regorafenib BARD1 KIT 7
regorafenib BARD1 RET 7
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin BARD1 TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin BARD1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel BARD1 RET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel BARD1 TYMS 2
alvocidib, paclitaxel BARD1 CDK9 2
apatinib, irinotecan BARD1 TOP1MT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BARD1 TOP1MT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BARD1 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine BARD1 TOP1MT 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine BARD1 TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 BARD1 TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BARD1 KIT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BARD1 TYMS 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis BARD1 TYMS 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging BARD1 TLR9 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging BARD1 TYMS 2
biospecimen collection, computed tomography, pemetrexed BARD1 TYMS 2
bortezomib BARD1 PSMB5 2
bryostatin 1, paclitaxel BARD1 PRKCE 2
cabozantinib BARD1 RET 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib BARD1 RET 2
capecitabine, carboplatin, epirubicin hydrochloride BARD1 TYMS 2
capecitabine, docetaxel BARD1 TYMS 2
capecitabine, irinotecan hydrochloride BARD1 TYMS 2
capecitabine, oxaliplatin BARD1 TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy BARD1 TYMS 2
capecitabine, temozolomide BARD1 TYMS 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy BARD1 CA3 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy BARD1 TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery BARD1 TYMS 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery BARD1 TOP1MT 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy BARD1 TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy BARD1 TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy BARD1 TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy BARD1 TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy BARD1 TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy BARD1 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab BARD1 TYMS 2
cpt- 11, cisplatin, celecoxib, radiation, surgery BARD1 CA3 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel BARD1 TYMS 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib BARD1 RET 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 BARD1 TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy BARD1 TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy BARD1 TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium BARD1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study BARD1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study BARD1 HDAC3 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study BARD1 TYMS 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy BARD1 TYMS 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a BARD1 KIT 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a BARD1 RET 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide BARD1 TOP1MT 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide BARD1 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib BARD1 TYMS 2
irinotecan, capecitabine BARD1 TOP1MT 2
irinotecan, capecitabine BARD1 TYMS 2
irinotecan, docetaxel BARD1 TOP1MT 2
laboratory biomarker analysis, oxaliplatin, pralatrexate BARD1 TYMS 2
lenvatinib, pembrolizumab BARD1 KIT 2
lenvatinib, pembrolizumab BARD1 RET 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate BARD1 KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate BARD1 RET 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab BARD1 TOP1MT 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab BARD1 TYMS 2
m6620, cisplatin, capecitabine, radiotherapy BARD1 TYMS 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells BARD1 CHRNB4 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed BARD1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a BARD1 KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a BARD1 RET 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a BARD1 TYMS 2
nab-paclitaxel, gemcitabine BARD1 TYMS 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine BARD1 TYMS 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu BARD1 TYMS 2
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis BARD1 TYMS 2
pembrolizumab, guadecitabine, mocetinostat BARD1 HDAC3 2
pembrolizumab, lenvatinib BARD1 KIT 2
pembrolizumab, lenvatinib BARD1 RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu BARD1 KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu BARD1 RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu BARD1 TYMS 2
pembrolizumab, paclitaxel, docetaxel, irinotecan BARD1 TOP1MT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BARD1 KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BARD1 RET 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BARD1 TYMS 2
pemetrexed, bevacizumab BARD1 TYMS 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography BARD1 TYMS 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery BARD1 RET 2
regorafenib, laboratory biomarker analysis BARD1 KIT 2
regorafenib, laboratory biomarker analysis BARD1 RET 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed BARD1 TYMS 2
sorafenib, administered orally, ct/mri BARD1 KIT 2
sorafenib, administered orally, ct/mri BARD1 RET 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel BARD1 TYMS 2
tislelizumab, pemetrexed BARD1 TYMS 2
topotecan BARD1 TOP1MT 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy BARD1 TYMS 2
carfilzomib BARD1 PSMB5 7
pemetrexed BARD1 TYMS 7
selpercatinib BARD1 RET 7
sorafenib BARD1 KIT 7
sorafenib BARD1 RET 7
vandetanib BARD1 RET 7
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy BARD1 TYMS 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging BARD1 TYMS 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat BARD1 HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) BARD1 TLR9 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat BARD1 HDAC3 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery BARD1 TYMS 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin BARD1 TOP1MT 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis BARD1 TYMS 1
7-hydroxystaurosporine, fluorouracil BARD1 TYMS 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan BARD1 TOP1MT 1
9-ing-41, retifanlimab, gemcitabine, abraxane BARD1 TYMS 1
abbv-400, budigalimab, fluorouracil, leucovorin, oxaliplatin BARD1 TYMS 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf BARD1 TOP1MT 1
abemaciclib, ly3023414, gemcitabine, capecitabine BARD1 TYMS 1
abraxane (nab-paclitaxel), gemcitabine BARD1 TYMS 1
acetazolamide, temozolomide BARD1 CA14 1
acetazolamide, temozolomide BARD1 CA3 1
actidose aqua, artesunate, amodiaquine BARD1 HNMT 1
adct-601, gemcitabine BARD1 TYMS 1
adebrelimab, apatinib, tegafur BARD1 TYMS 1
afatinib dimaleate, capecitabine, laboratory biomarker analysis BARD1 TYMS 1
afatinib, dasatinib, palbociclib, everolimus, olaparib BARD1 KIT 1
afatinib, irinotecan BARD1 TOP1MT 1
ag-013736, gemcitabine, gemcitabine, placebo BARD1 TYMS 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel BARD1 TYMS 1
ags-1c4d4, gemcitabine BARD1 TYMS 1
ak104, ak104, gemcitabine, nab-paclitaxel BARD1 TYMS 1
ak104, oxaliplatin, capecitabine BARD1 TYMS 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine BARD1 TYMS 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib BARD1 TYMS 1
albumin-bound paclitaxel (abi-007), gemcitabine BARD1 TYMS 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim BARD1 TYMS 1
aldoxorubicin, topotecan BARD1 TOP1MT 1
alisertib, gemcitabine BARD1 TYMS 1
alvocidib, docetaxel BARD1 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis BARD1 CDK9 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox BARD1 TYMS 1
amg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, capecitabine, cisplatin, capecitabine, cisplatin, capecitabine BARD1 TYMS 1
amg 479, placebo, amg 479, gemcitabine BARD1 TYMS 1
aminolevulinic acid BARD1 ALAD 1
aminolevulinic acid, surgical resection BARD1 ALAD 1
amrubicin, topotecan BARD1 TOP1MT 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel BARD1 TOP1MT 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel BARD1 TYMS 1
apg-1387 for injection, gemcitabine, nab paclitaxel BARD1 TYMS 1
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications BARD1 TYMS 1
apx005m, nivolumab, nab-paclitaxel, gemcitabine BARD1 TYMS 1
arq 197, gemcitabine BARD1 TYMS 1
ascorbate, nab paclitaxel, gemcitabine BARD1 TYMS 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine BARD1 EGLN3 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine BARD1 TYMS 1
askb589, oxaliplatin, capecitabine, tislelizumab, placebo BARD1 TYMS 1
at-101, topotecan BARD1 TOP1MT 1
atezolizumab, biospecimen collection, capecitabine, computed tomography, docetaxel, echocardiography, fluorouracil, leucovorin calcium, lymphadenectomy, magnetic resonance imaging, oxaliplatin, positron emission tomography, surgical procedure BARD1 TYMS 1
atezolizumab, cabozantinib BARD1 RET 1
atezolizumab, conventional surgery, fluorouracil, oxaliplatin, tiragolumab BARD1 TYMS 1
atezolizumab, tivozanib BARD1 KIT 1
atorvastatin, temozolomide, radiotherapy BARD1 NR1I3 1
atra, gemcitabine, nab-paclitaxel BARD1 TYMS 1
avapritinib, midazolam BARD1 KIT 1
avastin (bevacizumab), gemcitabine, radiation therapy BARD1 TYMS 1
avastin, bortezomib BARD1 PSMB5 1
avastin, temozolomide, irinotecan BARD1 TOP1MT 1
avastin, temozolomide, radiation therapy (xrt), irinotecan BARD1 TOP1MT 1
avelumab, irinotecan, paclitaxel, best supportive care (bsc) BARD1 TOP1MT 1
avelumab, oxaliplatin, 5-fluorouracil, leucovorin, capecitabine, best supportive care, oxaliplatin, 5-fluorouracil, leucovorin, capecitabine BARD1 TYMS 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab BARD1 HDAC3 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab BARD1 TYMS 1
azd0171, durvalumab, gemcitabine, nab-paclitaxel BARD1 TYMS 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine BARD1 TOP1MT 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine BARD1 TYMS 1
azd1775, gemcitabine, nab-paclitaxel BARD1 TYMS 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 BARD1 TOP1MT 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 BARD1 TYMS 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil BARD1 TOP1MT 1
berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging BARD1 TOP1MT 1
bethanechol, gemcitabine, nab-paclitaxel BARD1 TYMS 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.